Proteomic Characterization of High-Density Lipoprotein Particles from Non-Diabetic Hemodialysis Patients

被引:12
作者
Florens, Nans [1 ,2 ]
Calzada, Catherine [1 ]
Delolme, Frederic [3 ]
Page, Adeline [3 ]
Guebre Egziabher, Fitsum [1 ,2 ]
Juillard, Laurent [1 ,2 ]
Soulage, Christophe O. [1 ]
机构
[1] Univ Claude Bernard Lyon 1, Univ Lyon, INSA Lyon, CarMeN,INSERM,U1060,U1397,INRA, F-69621 Villeurbanne, France
[2] Hosp Civils Lyon, Hop E Herriot, Serv Nephrol Hypertens Hemodialyse, F-69003 Lyon, France
[3] Univ Claude Bernard Lyon 1, ENS Lyon, Prot Sci Facil, SFR BioSci,CNRS,UMS3444,Inserm,US8, F-69007 Lyon, France
关键词
HDL cholesterol; lipoproteins; cardiovascular risk; proteomic; mass spectrometry; hemodialysis; CARDIOVASCULAR EVENTS; HDL COMPOSITION; KIDNEY-DISEASE; MODALITIES; PROTEINS;
D O I
10.3390/toxins11110671
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Chronic kidney disease is associated with an increased cardiovascular risk, and altered biological properties of high-density lipoproteins (HDL) may play a role in these events. This study aimed to describe the HDL proteome from non-diabetic hemodialysis patients and identify potential pathways affected by the dysregulated expression of HDL proteins. HDL were sampled from nine non-diabetic hemodialysis (HD) and eight control patients. Samples were analyzed using a nano-RSLC coupled with a Q-Orbitrap. Data were processed by database searching using SequestHT against a human Swissprot database and quantified with a label-free quantification approach. Proteins that were in at least five of the eight control and six of the nine HD patients were analyzed. Analysis was based on pairwise ratios and the ANOVA hypothesis test. Among 522 potential proteins, 326 proteins were identified to be in the HDL proteome from HD and control patients, among which 10 were significantly upregulated and nine downregulated in HD patients compared to the control patients (p < 0.05). Up and downregulated proteins were involved in lipid metabolism, hemostasis, wound healing, oxidative stress, and apoptosis pathways. This difference in composition could partly explain HDL dysfunction in the chronic kidney disease (CKD) population and participate in the higher cardiovascular risk observed in this population.
引用
收藏
页数:10
相关论文
共 18 条
  • [11] Proteome profiles of HDL particles of patients with chronic heart failure are associated with immune response and also include bacteria proteins
    Oberbach, Andreas
    Adams, Volker
    Schlichting, Nadine
    Heinrich, Marco
    Kullnick, Yvonne
    Lehmann, Stefanie
    Lehmann, Sven
    Feder, Stefan
    Correia, Joao Carlos
    Mohr, Friedrich-Wilhelm
    Voelker, Uwe
    Jehmlich, Nico
    [J]. CLINICA CHIMICA ACTA, 2016, 453 : 114 - 122
  • [12] Quantifying HDL proteins by mass spectrometry: how many proteins are there and what are their functions?
    Shao, Baohai
    Heinecke, Jay W.
    [J]. EXPERT REVIEW OF PROTEOMICS, 2018, 15 (01) : 31 - 40
  • [13] A Cluster of Proteins Implicated in Kidney Disease Is Increased in High-Density Lipoprotein Isolated from Hemodialysis Subjects
    Shao, Baohai
    de Boer, Ian
    Tang, Chongren
    Mayer, Philip S.
    Zelnick, Leila
    Afkarian, Maryam
    Heinecke, Jay W.
    Himmelfarb, Jonathan
    [J]. JOURNAL OF PROTEOME RESEARCH, 2015, 14 (07) : 2792 - 2806
  • [14] HDL in Children with CKD Promotes Endothelial Dysfunction and an Abnormal Vascular Phenotype
    Shroff, Rukshana
    Speer, Thimoteus
    Colin, Sophie
    Charakida, Marietta
    Zewinger, Stephen
    Staels, Bart
    Chinetti-Gbaguidi, Giulia
    Hettrich, Inga
    Rohrer, Lucia
    O'Neill, Francis
    McLoughlin, Eve
    Long, David
    Shanahan, Catherine M.
    Landmesser, Ulf
    Fliser, Danilo
    Deanfield, John E.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2014, 25 (11): : 2658 - 2668
  • [15] Plasma Beta-Trace Protein as a Marker of Residual Renal Function: The Effect of Different Hemodialysis Modalities and Intra-Individual Variability over Time
    Van Craenenbroeck, Amaryllis H.
    Bragfors-Helin, Ann-Christin
    Qureshi, Abdul Rashid
    Lindholm, Bengt
    Sjoberg, Bodil
    Anderstam, Bjorn
    Heimburger, Olof
    Stenvinkel, Peter
    Barany, Peter
    [J]. KIDNEY & BLOOD PRESSURE RESEARCH, 2017, 42 (05) : 877 - 885
  • [16] Causes of Dysregulation of Lipid Metabolism in Chronic Renal Failure
    Vaziri, Nosratola D.
    [J]. SEMINARS IN DIALYSIS, 2009, 22 (06) : 644 - 651
  • [17] Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
    Wanner, C
    Krane, V
    März, W
    Olschewski, M
    Mann, JFE
    Ruf, G
    Ritz, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (03) : 238 - 248
  • [18] Dysfunctional High-Density Lipoprotein in Patients on Chronic Hemodialysis
    Yamamoto, Suguru
    Yancey, Patricia G.
    Ikizler, Alp
    Jerome, W. Gray
    Kaseda, Ryohei
    Cox, Brian
    Bian, Aihua
    Shintani, Ayumi
    Fogo, Agnes B.
    Linton, MacRae F.
    Fazio, Sergio
    Kon, Valentina
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (23) : 2372 - 2379